MULTIMEDIA UPDATE — Game, Set, Match: JOE & THE JUICE Welcomes Novak Djokovic to the Family

Global lifestyle brand JOE & THE JUICE and tennis GOAT Novak Djokovic are joining forces to redefine functional health, one sip at a time

COPENHAGEN, Denmark, June 5 (Bernama-GLOBE NEWSWIRE) — Today, JOE & THE JUICE, the global concept known for its electric vibes, killer tunes, and seriously great sips, is proud to announce a strategic partnership with tennis legend (currently breaking records on court) and Olympic gold medalist, Novak Djokovic. More than just a collaboration, Djokovic is stepping onto the court as a Health & Wellness Ambassador and a shareholder, ready to lend his champion mindset to the brand. 

“I’m proud to announce my new role as a Health & Wellness Ambassador for Joe & The Juice,” says Novak Djokovic. “Throughout my career, physical and mental wellness have been the foundation of my performance on and off the court. From training and recovery to nutrition and mindset, I’ve learned that what you put into your body directly impacts how far you can push it.

Joe & The Juice shares that same commitment to clean ingredients, energy, and balance. I’ve long admired their fresh, functional approach to fuelling the body and mind – whether it’s a pre-match juice or a mid-day reset. Together, we’ll be working on bringing purposeful wellness to more people around the world.”

As an all-time record holder with 24-Grand Slam singles titles, remaining as world no.1 for a record 428 weeks, Djokovic knows what it takes to fuel the body and mind for success. These values resonate deeply with what JOE & THE JUICE stands for. Djokovic’s unapologetic approach to living well aligns intrinsically with JOE’s core values. 

“We believe in making better-for-you options accessible and inspiring a balanced and vibrant way of living,” says Thomas Nørøxe, CEO of JOE & THE JUICE. “Bringing Novak into the JOE family means enhancing that philosophy and reaching even more people. He’s a global icon who embodies well-being and authenticity – values central to who we are. This partnership is about growing together and continuing to empower people to elevate their lifestyle. And trust me, we’re just getting started.” 

As this long-term partnership unfolds, Djokovic will be an active participant within the JOE & THE JUICE world, contributing to brand campaigns, offering valuable input for product development, and sharing his unique perspective on wellness and performance.  

And for those who know, you know that JOE & THE JUICE has always been about pushing boundaries. With Novak Djokovic’s support, we’re planting roots deeper, specifically through his involvement in developing the JOE & THE JUICE franchise in Serbia and Montenegro. This is about bringing the unique JOE experience to more people than ever before, starting in a region close to Novak’s heart. 

With a presence across 400+ locations worldwide, JOE & THE JUICE continues to expand its footprint as the primary health-centric lifestyle destination.  

Keep an eye on our channels for the first powerful activation, dropping later this year. The blend just got stronger.

Related link:Novak Djokovic x Joe & the Juice, Instagram Announcement

A photo accompanying this announcement is available at 
https://www.globenewswire.com/NewsRoom/AttachmentNg/7173bc3a-3cdf-4973-aa2a-614878390dbf

Press contact Sabine Fabrin
E-mail: sabine.fabrin@joejuice.com

SOURCE: Joe & The Juice A/S

–BERNAMA

TIME FOR ASSURERS TO ACT FOR THE BENEFIT OF POLICY OWNERS

KUALA LUMPUR, March 24 (Bernama) —

Introduction

Despite calls to engage insurers privately and not moot their points through media, APHM continues airing its concerns publicly. The general public couldn’t care less about this issue. These are private matters between APHM and Insurers. As mentioned in the same article, the relationship between private hospitals and insurers is best described as symbiotic. APHM must find solutions that flourish this relationship rather than be parasitic.  

APHM proposes the formation of a joint working committee between the association and Assurers to review billing structures and ensure fair pricing of healthcare services. It is a good start, but it needs to focus its energy on the core matter, the burdening hospital charges that cause assurers to increase their prices. The billing structure and so-called fair pricing don’t solve the current problems. It is more of an academic exercise. 

APHM’s public statements call for assurers to keep cashless medical products while using patient care as a smoke screen. It is a ruse to maintain its top and bottom line, and its sincerity can be seen when it issued a statement rejecting Assurer’s proposal for private hospitals to freeze costs for three years and also for the Health Ministry to regulate the pricing of pharmaceuticals or medication during the period assurers facing premium pricing caps. 
Public Education
Since APHM is only interested in making public statements to try to arouse policyholders’ sentiments to protect their cash flow and profit margins, it is time for assurers to take steps to protect policy owners’ interests. The public is concerned about rising health premiums. They don’t understand the reasons behind it.   

Therefore, assurers need to expand their role in public education on how assurers develop their product prices. Most of the cost goes toward paying claims, distribution costs, and maintaining statutory reserves. Assurers must demonstrate how much premium is allocated to companies as their pretax profits for every ringgit of premium received. 

Public education goes a long way and will make the public understand the financial burden caused by APHM members.

Cheaper, Scalable & Customized Direct Products
Policy owners deserve access to cheaper health assurance products. Insurers can consider two critical modifiable parameters: direct distribution without going through agents and selling the product on a reimbursement basis. Distribution through agents is costly. Technology today allows companies to educate customers on product features with ease. Product distribution has greater depth today.  

Assurers can develop tier products that cover the treatment of medical risks for specific age groups. The young have a lesser risk of admission due to chronic illnesses. The sum cover can be lowered since the cost of treatment for acute illnesses and injuries is low. Employees can buy a small sum for the employed category to cover health top-up products, where the primary claim should be against the employer’s paid assurance. The top-up is used only when the primary product limits are exhausted. 

The second strategy would be reintroducing reimbursement-based products. It has dual key advantages. First, the policy owners are responsible for controlling hospital bill expenses. Coupled with BNM directives of Co-payment, policy owners would question their hospital charges. Introducing Co-pay reimbursement products is within the assurer’s rights. We cannot blame APHMs for making public statements and calling for assurers to keep cashless medical products as they know it significantly impacts their earnings. 

The third strategy is for assurers to revisit and expand the strategy they introduced in early 2000, where they formed a consortium that markets national health assurance products instead of individual company products. An industry-wide product allows the consolidation of claim data to determine the true industry burning costs. More importantly, consolidating policy owners’ data enables the industry to spread costs and introduce cheaper products. Individual assurance companies only need to focus on distribution and customer service. The focus would be on customer service. This approach would be the seed of the National Health Assurance under the assurance industry-driven National Healthcare Financing System. 

Under this approach, the competition among the assurance companies is no longer on pricing. The law of large numbers dictates and has an impact on price. However, if private hospitals continue to have the unchecked freedom to determine the charges, the proposed measures will only temporarily reprieve policy owners.   

Conclusion
In the best interest of policy owners & to protect them against increasing premiums, re-introducing reimbursement health products would be the best approach. Policy owners themselves must take the role of questioning hospital charges, which directly impacts health assurance premiums. 

Assurers must develop products that limit the benefit payment according to age, gender, pre-existing conditions and risk exposure. A young person who enjoys employer insurance coverage does not need an RM1000,000 sum of cover. Having high annual and lifetime limits promotes “medical inflation”. 

Assurers must get their act together as an industry, focus on their policy owners, ignore APHM public statements and develop a structured public education program explaining how assurers’ price their products.

21-3-2025  

Dr Mohamed Rafick Khan 
Reassurer and Assurance Industry Consultant

Dr. Mohamed Rafick is a trained physician with 12 years of experience in military medical services and over 22 years of experience in the assurance industry. He retired as the CEO of a multinational reinsurance company in 2019. Currently, he remains active as an independent international assurance industry consultant.

SOURCE: Dr Mohamed Rafick Khan 
Reassurer and Assurance Industry Consultant

FOR MORE INFORMATION, PLEASE CONTACT:
Name: Dr Rafick 
Tel: 012 2218956
Email: drrafick@gmail.com

–BERNAMA

MERZ AESTHETICS REVEALS GLOBAL DATA ON THE CONNECTION BETWEEN CONFIDENCE, SELF-AFFIRMATION AND AESTHETIC TREATMENTS

Graphic: Merz Aesthetics

New Research Suggests that People Seek Aesthetic Treatments to Align Inner Self with Outward Appearance

RALEIGH, N.C., Jan 31 (Bernama-BUSINESS WIRE) — Merz Aesthetics, the world’s largest dedicated medical aesthetics business, today announced the findings of its inaugural global study, Pillars of Confidence: Global Insights on Aesthetics and Self-AffirmationThe study explored the role confidence plays in daily life and overall well-being, as well as the connection between our internal selves and outward expression.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250129954824/en/

As part of its Confidence to Be platform, Merz Aesthetics surveyed 15,000 adults from around the world who have had an aesthetic treatment in the past or are open to having one in the near future. The Pillars of Confidence study revealed that a global majority of study participants have a strong sense of self-confidence, with 72% agreeing with the statement, “I am confident in who I am.”

The findings of the Pillars of Confidence study also link external appearance to internal self-concept. When it comes to aesthetic treatments specifically, 73% of respondents reported saying they feel “empowered” after having an aesthetic treatment, 69% seek aesthetic treatments to reflect how they feel inside and 72% said that aesthetic treatments impact how they view themselves.

Conducted in partnership with Ipsos*, one of the largest market research and polling companies globally, the Pillars of Confidence study engaged 15,000 adults aged 21 to 75** from 15 countries. Participating regions and countries included:

  • Asia-Pacific: China, South Korea, Thailand
  • Europe, the Middle East & Africa: France, Germany, Italy, Spain, the United Kingdom and the United Arab Emirates
  • Latin America: Brazil, Colombia, Costa Rica, Mexico
  • North America: United States, Canada

“Since becoming a standalone global business nearly five years ago, Merz Aesthetics has been committed to our purpose of fueling confidence by helping people look better, feel better and live better. We believe in the importance of feeling confident and what makes you feel like the best version of yourself—however you define it,” said Bob Rhatigan, CEO, Merz Aesthetics. “Our Pillars of Confidence research shows what we anecdotally knew to be true—that aesthetic treatments appear to do more than just enhance our appearance; they can help people feel empowered and support their self-confidence journey.”

“The Pillars of Confidence data shows how aesthetic treatments enable patients to take an active role in aligning their self-perception with their outward appearance,” said Dr. Shannon Humphrey, cosmetic dermatologist, medical director at Humphrey & Beleznay Cosmetic Dermatology and clinical associate professor at the University of British Columbia. “As a physician, I see this impact every day. These insights can help us better understand and support our patients as they work toward personal empowerment, which ultimately enhances the care we provide.”

Whether it’s the things we say, the people we surround ourselves with, or our choices around aesthetic treatments, Merz Aesthetics believes that every person’s journey to look, feel and live their best is unique. With a purpose to fuel confidence worldwide, Merz Aesthetics hopes that the data-backed insights of the Pillars of Confidence study will inspire meaningful conversations that enable even more people to celebrate being their authentic selves, both inside and out.

For more information on the Pillars of Confidence study and to download a full report of the findings, please visit www.merzaesthetics.com/confidence.

*Merz Aesthetics. (2025). Pillars of Confidence: Global Insights on Aesthetics and Self-Affirmation. Supported by research partner Ipsos.

**Age range in Asia-Pacific region was 21 to 65.

About Merz Aesthetics

Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.

© 2025 Merz North America, Inc. All rights reserved. Merz, Merz Aesthetics and the Merz Aesthetics Confidence To Be Logo are trademarks and/or registered trademarks of Merz Pharma GmbH & Co. KGaA in the U.S. and/or certain other countries.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20250129954824/en/

Contact

Media Contact
Merz Aesthetics
Global Corporate Communications
6501 Six Forks Road, Raleigh NC 27615
919-302-3296
media@merz.com

Source : Merz Aesthetics

NEOVIVA, SWITZERLAND’S FIRST ADDICTION CLINIC OFFERING GUARANTEE

LUCERNE, Switzerland, Jan 21 (Bernama-GLOBE NEWSWIRE) — Neoviva, a leading luxury rehab centre launches Switzerland’s first and only assurance programme in addiction treatment. With a structured and tailored approach, Neoviva’s programme addresses the unique needs of each client, blending cutting-edge therapeutic methods with comprehensive aftercare. The Neoviva Guarantee is a testament to the effectiveness of their personalised Signature Programme and reflects confidence in the programme’s ability to help clients achieve sustainable recovery.

“Our track record speaks for itself, with countless success stories of lasting recovery. The Neoviva Guarantee is our way of putting action behind our words. We’re so convinced of our programme’s efficacy that we’re willing to stand by our clients long after they leave our facility. This isn’t just treatment; it’s a lifelong partnership in recovery,” states Fenina Erpf, CEO and Co-Founder of NEOVIVA, alongside Oliver Neubert, Founder of NEOVIVA.

Clients who complete a minimum of six weeks of Neoviva’s Signature programme and adhere to the 30-week continuing care plan are eligible for the Guarantee. Should a client relapse within one year of completing the programme, they may return for up to four weeks of additional intensive treatment at no extra cost.*

Nestled on the tranquil shores of Lake Lucerne, NEOVIVA’s luxury rehab facility blends world-class care with an exclusive and serene environment. Housed within a real-life hotel setting, our clinic offers the perfect balance of comfort, privacy, and discretion, ensuring a supportive space for recovery. This unique setting empowers clients with the tools and strategies needed to navigate life beyond treatment, all while immersed in the breathtaking beauty of the Swiss Alps.

About Neoviva:

Neoviva is a luxury rehab centre in Switzerland that offers personalised treatment plans for mental health and addiction treatment. With pioneering methodologies, a high staff-to-client ratio, and a commitment to profound personal transformation, Neoviva is more than a rehab centre—it is a life-changing experience for those seeking lasting recovery.

*Terms and conditions apply.

A photo accompanying this announcement is available at 
https://www.globenewswire.com/NewsRoom/AttachmentNg/22e5d7be-00e5-4d4c-9f88-fde0ffc48718

For more information, please contact:

Fenina Erpf

CEO & Co-Founder

fenina.erpf@neoviva.com

6354 Vitznau

Switzerland

Phone: +41 58 100 08 00

SOURCE: NEOVIVA AG

–BERNAMA

ZENAS BIOPHARMA TO PARTICIPATE IN UPCOMING HEALTHCARE INVESTOR CONFERENCES

WALTHAM, Mass, 8 Nov (Bernama-GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the Company’s participation at the following healthcare investor conferences:

  • Guggenheim’s Inaugural Healthcare Innovation Conference on November 12, 2024, in Boston, MA
  • Jefferies London Healthcare Conference on November 19, 2024 presentation at 4:00 p.m. to 4:25 p.m. GDT, in London
  • Citi’s 2024 Global Healthcare Conference on December 3, 2024 presentation at 9:30 a.m. to 10:10 a.m. ET, in Miami, FL
  • Evercore ISI HealthCONx Conference on December 4, 2024 presentation at 1:20 p.m. to 1:40 p.m. ET, in Coral Gables, FL

Live webcasts and archived replays of the Company’s presentations at the Jefferies, Citi and Evercore conferences can be accessed under “Events and Presentations” in the Investors and Media section of the Zenas BioPharma website.

About Zenas BioPharma, Inc.

Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative immunology-based therapies for patients in need. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s mechanism of action and chronic dosing regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on X at @ZenasBioPharma and LinkedIn.

The Zenas BioPharma word mark and logos are trademarks of Zenas BioPharma, Inc. or its affiliated companies.

Investor Contact:
Matthew Osborne
Investor Relations and Corporate Communications
Matt.osborne@zenasbio.com

Media Contact:
Argot Partners
Zenas@argotpartners.com

SOURCE : Zenas BioPharma (USA) LLC